CDI Quality Institute | Provider Led Entity

Nearby Locations

Provider Led Entity

In June of 2016, the Centers for Medicare and Medicaid (CMS) named the RAYUS Quality Institute as one of the qualified Provider Led Entities (PLE) to assist in fulfilling the ambitious mandate in the 2014 federal Protecting Access to Medicare Act. The mandate will better assure that all Medicare patients receive the right imaging test at the right time.

The Institute’s governing board of physicians is devoted to developing appropriate use criteria (AUC) based on clinical evidence that is also of practical use for community-based physicians.

Below, please find answers to questions you may have about our Provider Led Entity.

Multidisciplinary Committee

The RAYUS Quality Institute serves as the provider-led entity (PLE) and the Institute’s PLE Multidisciplinary Committee serves as the multidisciplinary team. Certain functions and responsibilities are performed by contract with third parties.

2024 Multidisciplinary Committee Members:

  • Thomas J. Gilbert, MD, MPP – Chair
  • Robert Liddell, MD – Vice Chair
  • Lawrence Cowsill, DO, FACOI
  • Michael Ulissey, MD, FACR
  • Vincent Mathews, MD, FACR
  • Steven R. Pollei, MD
  • Kellie Schenk, MD
  • Michael Finch, PhD
  • Paul Allegra, MD
  • Erik Rockswold, MHA, MA

Under formal resolution by the RAYUS Quality Institute’s Council of Medical Directors, the PLE Multidisciplinary Committee is a free-standing committee within the Institute, created for the purpose of administering all of the functions of the multidisciplinary team as set forth in the federal regulations. This structure provides for the necessary transparency, autonomy and accountability in carrying out this responsibility. The PLE Multidisciplinary Committee has the following characteristics:

  • Members have been appointed by the Executive Committee from among the Members of the Council and employees of the Medical Practices that participate in the Institute, or from affiliated entities where there has been a demonstrated commitment to high quality, community-based health care services as well as for their independent professional judgment. These members serve indefinite terms, subject to removal for good cause and upon two-thirds vote of the Executive Committee.
  • Statistical Analysis support is provided by Michael Finch, PhD.
  • The PLE Multidisciplinary Committee’s determinations will not be subject to modification or rejection by The RAYUS Quality Institute, its Members, its Executive Committee or any other party.

AUC Library

The Multidisciplinary Committee is the initial and final authority on all Appropriate Use Criteria. For each clinical topic area, the Multidisciplinary Committee convenes subject expert panels, consisting of the individuals listed below, to provide an additional level of review and advice on current evidence- and consensus-based practices.

With the Institute’s commitment to prioritize areas of most use to community-based physicians while also adhering to the spirit and intent of the PAMA law and implementation regulations, the following Appropriate Use Criteria (AUC) areas have been developed:

AUC Development & Evidentiary Review Process:

The RAYUS Quality Institute PLE’s evidentiary review process adheres to the following steps in developing appropriate use criteria (AUC).

The RAYUS Quality Institute PLE’s Multidisciplinary Committee (MDC) is ultimately responsible to assess the quality of evidence for the AUC topic areas. The MDC convenes expert panels to further inform its decision making.

  1. For each subject area, our process includes an initial set of investigational questions, which we develop using the Patient/Problem, Interventions, Comparison, Outcome (PICO) framework. Those initial questions are reviewed, modified, and approved by the MDC.
  2. For all topics, the RAYUS Quality Institute PLE undertakes a literature search and grading process using the AGREE II instrument and the GRADE approach.
    CDI QI PLE Strength of a Body of Evidence
  3. The results of the literature search and grading process are reviewed and our PLE statistician may modify the result. Our PLE Chair and support staff then develop a draft AUC narrative that synopsizes the relevant evidence and recommendations.
    CDI QI PLE Strength of Recommendation
  4. The expert panel then meets to review the draft AUC, and to discuss and modify as appropriate. The federal regulations require that “to the extent feasible” our AUC should be evidence-based; the regulations also require that we identify key points in each particular criterion as being evidence-based or consensus-based. We consider consensus statements developed by medical specialty societies and similar organizations.
  5. After the expert panel meets, the modified draft AUC is presented to the MDC for further review and discussion. Following approval by the MDC, the final AUC are published on the RAYUS Quality Institute PLE website, together with all authoring and supporting documentation.
  6. The AUC and supporting documentation for clinical priority areas, as defined by CMS, are reviewed and updated on an annual basis.

Conflicts of Interest

The RAYUS Quality Institute and our PLE have a robust policy to address the issue of actual or perceived conflicts of interest.  The policy was reviewed and approved by the Federal government as part of our qualification process.  Any director, principal officer or member of the PLE Committee, or any person who participates in the Committee’s efforts to develop or modify AUC is subject to this policy.  Persons subject to the policy must disclose (and update) any ownership, investment, compensation or other financial interest with a broad range of stakeholders and are subject to exclusion from participation in the AUC development process based on certain criteria.  The policy is implemented and overseen by the PLE Administrator.

  • To read our Conflicts of Interest Policy, click here
  • To view our Conflicts of Interest reporting form, click here

Contact Us

Erik Rockswold, PLE Administrator

Christopher “Kit” Crancer, Institute Director